Only 8 ketoacidosis events were reported during the 52-week trial.[17] The above 2 studies demonstrate that GLP-1RA is effective in treating type 1 diabetes by stimulating insulin secretion and biosynthesis that are glucose-dependent, inhibiting glucagon secretion and gastric emptying, and reducing food intake. Here, INS is linked to type 1 diabetes mellitus.